IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Rish Pai  1     Gert De Hertogh  2     Walter Reinisch  3     Noam Harpaz  4     Brian G. Feagan  5     Noah Agada  6     Paul Pollack  6     Lai Shan Chan  6     Marijana Protic  6     Fernando Magro  7    
1 Mayo Clinic, Indianapolis, United States
2 University Hospitals Leuven, Leuven, Belgium
3 Medical University Vienna, Vienna, Austria
4 Icahn School of Medicine, New York, United States
5 Robarts Clinical Trials Inc., Ontario, Canada
6 Eli Lilly and Company, Indianapolis, United States
7 University of Porto, Porto, Portugal

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing